Results 191 to 200 of about 68,113 (243)

Antibody-Dependent Cellular Phagocytosis and Cytotoxicity in Patients With LGI1 and CASPR2 Encephalitis. [PDF]

open access: yesNeurol Neuroimmunol Neuroinflamm
Businaro P   +24 more
europepmc   +1 more source

Unveiling the Taxonomic Diversity and Unprecedented Biosynthetic Treasure of the Phylum Myxococcota

open access: yesAdvanced Science, EarlyView.
Natural products remain vital sources of therapeutics, and the phylum Myxococcota constitutes an especially rich reservoir for them. Based on decades of microbiological efforts, we present 154 new Myxococcota genomes and revise taxonomy quadrupling the number of families and genera.
Amay Ajaykumar Agrawal   +25 more
wiley   +1 more source

Continuous Evolution System Based on Toxin–Antitoxin System Combined with Base Deaminase Accelerates the In Vivo Modification of Target Proteins

open access: yesAdvanced Science, EarlyView.
The promoted Escherichia coli‐assisted continuous evolution (PEACE) system operates through a stringent three step genetic circuit: target gene mutation via a deaminase–T7 RNA polymerase (T7 RNAP) fusion, coupling variant function to antitoxin expression, and growth based selection of surviving cells.
Xinyu Zhang   +10 more
wiley   +1 more source

Incidence and implications of anti-rituximab antibodies in nephropathies and other immune-mediated diseases: a narrative review. [PDF]

open access: yesFront Immunol
Allinovi M   +8 more
europepmc   +1 more source

Endovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity

open access: yesEndovascular trophoblast expresses CD59 to evade complement-dependent cytotoxicity
openaire   +1 more source

Complement dependent cytotoxicity in chronic lymphocytic leukemia: ofatumumab enhances alemtuzumab complement dependent cytotoxicity and reveals cells resistant to activated complement [PDF]

open access: yesLeukemia and Lymphoma, 2012
Complement dependent cytotoxicity (CDC) is an important mechanism of action for monoclonal antibodies (mAbs) used in the treatment of chronic lymphocytic leukemia (CLL). We hypothesized that alemtuzumab (ALM) mediated CDC would be increased by the addition of ofatumumab (OFA).
Clive S Zent   +2 more
exaly   +3 more sources

Home - About - Disclaimer - Privacy